Visual Abstract

ATOS was a 12-month prospective observational study in 18 countries outside US and Western Europe in insulin-naïve adults with T2DM, uncontrolled (HbA1c >7-≤11%) on ≥1 oral anti-hyperglycemic drug. This subgroup analysis of ATOS compared the effectiveness and safety of Gla-300 in older (≥70 years [Y]; N=514) and younger (<70 Y; N=3908) adults. People aged ≥70 Y had a longer duration of T2DM and more comorbidities than those aged <70 Y. Physician-set individualized HbA1c (%) goals at baseline in the <70 vs. ≥70 Y groups were <7: 14.6 vs. 6.2%; 7-<7.5: 72.9 vs. 52.1%; 7.5-<8: 9.3 vs. 30.9%; ≥8: 3.2 vs. 10.7%. HbA1c target achievement was higher in the older population than in the <70 Y age group: Month 6 (32.3%, vs. 24.2%) and Month 12 (53.2% vs. 43.4%). HbA1c reductions from baseline to Month 6 (-1.48 vs. -1.51%) and Month 12 (-1.76 vs. -1.89%) were similar in both groups. A very low rate of hypoglycemia was reported, although numerically higher in ≥70 Y group. Increases in the Gla-300 dose was similar across the groups. Incidence of any and serious treatment-emergent adverse events was low. Consistent results were observed in subgroup of <65 vs. ≥65 Y. Initiation of Gla-300 in the older adults is effective in achieving their pre-defined HbA1c goals with low risk of hypoglycemia in both older and younger adults with T2DM.


G. R. Galstyan: None. A. Tirosh: Advisory Panel; Self; AstraZeneca, Eli Lilly and Company, Novo Nordisk, Sanofi, Consultant; Self; DreaMed Diabetes, Ltd. H. Vargas-uricoechea: Advisory Panel; Spouse/Partner; Sanofi. M. N. Mabunay: Employee; Self; Sanofi, Stock/Shareholder; Self; Sanofi. M. Coudert: Employee; Self; Sanofi. V. Pilorget: Employee; Self; Sanofi. N. Khan: None.



Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at